Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX15 Belantamab mafodotin
D11595 Belantamab mafodotin (USAN)
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Anti-BCMA Antibodies
Belantamab Mafodotin
D11595 Belantamab mafodotin (USAN)
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
Tumor necrosis factor receptors
TNFRSF17 (BCMA, CD269)
D11595 Belantamab mafodotin (USAN)
Not elsewhere classified
Cellular process
Cytoskeleton
TUBB
D11595 Belantamab mafodotin (USAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11595
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11595
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11595
